» Articles » PMID: 16735171

Control of Cystic Echinococcosis/hydatidosis: 1863-2002

Overview
Journal Adv Parasitol
Specialty Parasitology
Date 2006 Jun 1
PMID 16735171
Citations 79
Authors
Affiliations
Soon will be listed here.
Abstract

Echinococcosis/hydatidosis, caused by Echinococcus granulosus, is a chronic and debilitating zoonotic larval cestode infection in humans, which is principally transmitted between dogs and domestic livestock, particularly sheep. Human hydatid disease occurs in almost all pastoral communities and rangeland areas of the underdeveloped and developed world. Control programmes against hydatidosis have been implemented in several endemic countries, states, provinces, districts or regions to reduce or eliminate cystic echinococcosis (CE) as a public health problem. This review assesses the impact of 13 of the hydatid control programmes implemented, since the first was introduced in Iceland in 1863. Five island-based control programmes (Iceland, New Zealand, Tasmania, Falklands and Cyprus) resulted, over various intervention periods (from <15 to >50 years), in successful control of transmission as evidenced by major reduction in incidence rates of human CE, and prevalence levels in sheep and dogs. By 2002, two countries, Iceland and New Zealand, and one island-state, Tasmania, had already declared that hydatid disease had been eliminated from their territories. Other hydatid programmes implemented in South America (Argentina, Chile, Uruguay), in Europe (mid-Wales, Sardinia) and in East Africa (northwest Kenya), showed varying degrees of success, but some were considered as having failed. Reasons for the eventual success of certain hydatid control programmes and the problems encountered in others are analysed and discussed, and recommendations for likely optimal approaches considered. The application of new control tools, including use of a hydatid vaccine, are also considered.

Citing Articles

The Effect of Lamb Vaccination Against Echinococcosis on the Scale of Livestock Farming in Northwestern China.

Liu B, Chen Q, Cai J, Li J, Liu Y Vet Med Sci. 2025; 11(2):e70273.

PMID: 40028713 PMC: 11875069. DOI: 10.1002/vms3.70273.


Reemergence of Echinococcus granulosus Infections after 2004 Termination of Control Program in Magallanes Region, Chile.

Alvarez Rojas C, Alvarez J Emerg Infect Dis. 2025; 31(2):373-376.

PMID: 39983684 PMC: 11845154. DOI: 10.3201/eid3102.240980.


[Controlling cystic echinococcosis: outlook in the 21st centuryControle da equinococose/hidatidose cística: perspectivas no século XXI].

Larrieu E, Alves R, Vigilato M Rev Panam Salud Publica. 2025; 49():e13.

PMID: 39811042 PMC: 11726123. DOI: 10.26633/RPSP.2025.13.


A Ferritin-Based Eg95 Nanoparticle Vaccine Adjuvanted with pCpG Eliciting Robust Immune Responses Against Cystic Echinococcosis in Mice Model.

Gao X, Zhu X, Liu X, Zhou C, Shang Y, Wu T Int J Nanomedicine. 2025; 20():309-325.

PMID: 39802377 PMC: 11725278. DOI: 10.2147/IJN.S499938.


Echinococcus granulosus sensu lato control measures: a specific focus on vaccines for both definitive and intermediate hosts.

Borhani M, Fathi S, Harandi M, Casulli A, Ding J, Liu M Parasit Vectors. 2024; 17(1):533.

PMID: 39716337 PMC: 11665232. DOI: 10.1186/s13071-024-06581-2.